ALXO · Alx Oncology Holdings Inc · Webcasts, Transcripts & Audio
$1.02
+0.05 (+5.14%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Market Cap
$131.86M
Shares
129.27M
Volume · Nov 19
2.95M
Avg daily vol (3M)
1.17M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Alx Oncology Holdings Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Alx Oncology Holdings Inc (ALXO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-01
Alx Oncology Holdings Inc (ALXO) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Alx Oncology Holdings Inc (ALXO) November 18, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Alx Oncology Holdings Inc (ALXO) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Alx Oncology Holdings Inc (ALXO) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Alx Oncology Holdings Inc (ALXO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Alx Oncology Holdings Inc (ALXO) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2026 Earnings Call Transcript
Confident tone
EVO + zanidatumab HER2-positive breast cancer data (ESMO)
CD47 biomarker predictive value
ALX 2004 EGFR-targeted ADC program
Diluted EPS
$-0.17
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Alx Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Transcript
Confident tone
CD47 biomarker validation across HER2-positive tumors
Phase II ASPEN-09 breast cancer trial
ALX 2004 EGFR ADC dose escalation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Alx Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Transcript
Confident tone
Avorpicept development strategy / targeted IO positioning
ASPEN-06 / CD47 biomarker data in gastric cancer
Breast cancer phase 2 program
Diluted EPS
$-0.41
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Alx Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Transcript
Confident tone
CD47 as predictive biomarker for evorpacept
ASPEN-06 trial data and response rates
Breast cancer program redesign
Diluted EPS
$-0.49
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Alx Oncology Holdings Inc (ALXO) Q1 2025 Earnings Call
Diluted EPS
$-0.58
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Alx Oncology Holdings Inc (ALXO) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Alx Oncology Holdings Inc (ALXO) Q3 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–13 of 13 webcasts
Key facts
CIK
1810182
CUSIP
00166B105
13F (30d)
123 filings
108 filers
Visit website
Investor relations